Related Experiment Video
Updated: Jul 18, 2026

Evaluation of a Point-of-Care Testing Analyzer for Measuring Peripheral Blood Leukocytes
Published on: March 22, 2022
Validation of the Beckman Coulter AcT 5 diff analyzer in a reference laboratory
1Clinical Laboratories Unit, Valle de Hebron Hospital Complex, Barcelona, Spain. caulesa@vhebron.net
None:
At the Valle de Hebron Hospital's Central Laboratory, we have performed a study evaluating the performance, reliability, and practicability of the Beckman Coulter AcT 5 analyzer. The results observed with known controls showed within- and between-run imprecision of 1.05% to 6.97% for the basic hemogram parameters. With patient samples, the results were analogous, with within- and between-run imprecision of 1.33% to 5.98%. To complete the evaluation of the AcT 5 counter, we analyzed the influence of possible interfering factors such as the presence of jaundice, lipemia, hemolysis, platelet aggregates, and schistocytes on the results of the automated leukocyte differential as performed by the cell counter with the new chlorazol black stain. We studied the performance of the AcT 5 with regards to ease of use, speed, and cost. Finally, we evaluated the impact of introducing the AcT 5 counter into routine laboratory use as support to resolve problems raised with the Beckman Coulter GenS and LH-750 and the Bayer Advia 120 counters due to samples with interfering factors.

